AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Chemed Corporation Q2 Earnings Miss: Revenue in Line, EPS Down 23%
ByAinvest
Saturday, Aug 2, 2025 10:19 am ET1min read
Chemed Corporation reported Q2 earnings that missed EPS estimates by 23%, with revenues in line with predictions. Analysts have revised their forecasts, with revenues expected to reach $2.55b in 2025, a slight decline from the previous estimate. EPS is forecast to reduce 3.2% to $19.36 in 2025. The average price target fell 12% to $567, with a narrowed range of estimates.
Chemed Corporation (NYSE: CHE) reported its Q2 earnings on July 29, 2025, with earnings per share (EPS) coming in at $4.27, missing the consensus estimate of $6.02 by 23%. Revenue for the quarter was $618.8 million, in line with analyst expectations of $650.6 million. The company's net margin remained at 11.56% and return on equity at 25.94%.Analysts have revised their forecasts in response to the earnings report. Revenues are now expected to reach $2.55 billion in 2025, a slight decline from the previous estimate of $2.6 billion. EPS is forecast to reduce by 3.2% to $19.36 in 2025. The average price target has fallen 12% to $567, with a narrowed range of estimates [1].
Oppenheimer analysts reduced their price target for Chemed from $650 to $580, maintaining an "outperform" rating. Jefferies Financial Group set a "hold" rating and a $500 target price, while Royal Bank of Canada reissued an "outperform" rating with a $640 price target. Bank of America reduced their price objective from $708 to $650, setting a "buy" rating [1].
Chemed's dual capital return strategy, combining aggressive stock buybacks and disciplined dividend growth, continues to attract investor attention. In Q2 2025, the company repurchased 75,000 shares for $42.9 million, averaging $572.61 per share. The quarterly dividend has surged from $0.34 to $0.50 per share, reflecting a 25% annualized growth rate [2].
The company's balance sheet remains strong, with a debt-to-equity ratio of 0.12 and 55 years of uninterrupted dividend payments. Management views share repurchases as a strategic response to short-term volatility and a signal of confidence in the company's long-term moats.
References:
[1] https://www.marketbeat.com/instant-alerts/chemed-nyseche-given-new-58000-price-target-at-oppenheimer-2025-07-31/
[2] https://www.ainvest.com/news/chemed-corporation-dual-capital-return-strategy-blueprint-shareholder-healthcare-sector-2508/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet